Oladapo Yeku

3.8k total citations · 2 hit papers
70 papers, 2.5k citations indexed

About

Oladapo Yeku is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Oladapo Yeku has authored 70 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 20 papers in Molecular Biology and 20 papers in Immunology. Recurrent topics in Oladapo Yeku's work include CAR-T cell therapy research (18 papers), Ovarian cancer diagnosis and treatment (17 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Oladapo Yeku is often cited by papers focused on CAR-T cell therapy research (18 papers), Ovarian cancer diagnosis and treatment (17 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Oladapo Yeku collaborates with scholars based in United States, Japan and Canada. Oladapo Yeku's co-authors include Renier J. Brentjens, Terence J. Purdon, David R. Spriggs, Mythili Koneru, Dayenne G. van Leeuwen, Michael A. Frohman, Xinghuo Li, Sarwish Rafiq, Mei Song and Xiaojing Ma and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Oladapo Yeku

60 papers receiving 2.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

2018 628 citations Sarwish Rafiq, Oladapo Yeku et al. Nature Biotechnology profile →
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma

2019 198 citations Oladapo Yeku, David R. Spriggs et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Oladapo Yeku United States	17	1.7k	894	835	586	451	70	2.5k
Kheng Newick United States	14	1.9k 1.1×	819 0.9×	897 1.1×	608 1.0×	445 1.0×	15	2.4k
Christopher S. Hackett United States	18	1.1k 0.6×	1.1k 1.2×	504 0.6×	339 0.6×	375 0.8×	25	2.3k
Stefanie R. Bailey United States	19	1.6k 0.9×	699 0.8×	1.1k 1.3×	468 0.8×	383 0.8×	35	2.3k
Tori N. Yamamoto United States	17	1.4k 0.8×	875 1.0×	1.2k 1.5×	365 0.6×	308 0.7×	21	2.5k
Magnus Essand Sweden	34	1.9k 1.1×	1.6k 1.8×	1.4k 1.7×	351 0.6×	1.1k 2.4×	124	4.1k
Haiying Qin United States	19	1.6k 0.9×	742 0.8×	654 0.8×	468 0.8×	558 1.2×	41	2.1k
Carol Box United Kingdom	20	961 0.6×	778 0.9×	279 0.3×	481 0.8×	167 0.4×	32	1.8k
Jillian Smith United States	8	1.8k 1.1×	541 0.6×	1.1k 1.3×	574 1.0×	390 0.9×	16	2.2k
Kunhong Zhong China	15	638 0.4×	672 0.8×	338 0.4×	170 0.3×	179 0.4×	32	1.4k
Susana Minguet Germany	25	794 0.5×	900 1.0×	1.1k 1.3×	224 0.4×	99 0.2×	63	2.5k

Countries citing papers authored by Oladapo Yeku

Since Specialization

Citations

This map shows the geographic impact of Oladapo Yeku's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oladapo Yeku with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oladapo Yeku more than expected).

Fields of papers citing papers by Oladapo Yeku

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oladapo Yeku. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oladapo Yeku. The network helps show where Oladapo Yeku may publish in the future.

Co-authorship network of co-authors of Oladapo Yeku

This figure shows the co-authorship network connecting the top 25 collaborators of Oladapo Yeku. A scholar is included among the top collaborators of Oladapo Yeku based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oladapo Yeku. Oladapo Yeku is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sullivan, Ryan J., Oladapo Yeku, Deanna Teoh, et al.. (2025). First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer. The Oncologist. 30(6). 2 indexed citations

Konstantinopoulos, Panagiotis A., Elizabeth K. Lee, Carolyn Krasner, et al.. (2025). Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer. JCO Precision Oncology. 9(9). e2400882–e2400882.

Kumar, Raj, et al.. (2025). CCR2 improves tumor directed CAR-T cell trafficking in ovarian cancer. Frontiers in Pharmacology. 16. 1651526–1651526.

Liu, Joyce F., Stéphanie Gaillard, Andrea E. Wahner Hendrickson, et al.. (2024). Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO Precision Oncology. 8(8). e2300693–e2300693. 6 indexed citations

Lee, Kwangkook, Kay Perry, Raj Kumar, et al.. (2024). Structural basis for antibody recognition of the proximal MUC16 ectodomain. Journal of Ovarian Research. 17(1). 41–41. 4 indexed citations

Lee, Eric, Oladapo Yeku, Ira Winer, et al.. (2024). 719MO A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer. Annals of Oncology. 35. S550–S550. 3 indexed citations

Starodub, Alexander, Sung‐Bae Kim, Diwakar Davar, et al.. (2024). TransCon IL-2 β/γ alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study.. Journal of Clinical Oncology. 42(16_suppl). 2601–2601. 1 indexed citations

Coté, Gregory M., Bose Kochupurakkal, T. Khanh, et al.. (2024). A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors. Clinical Cancer Research. 31(1). 35–44. 4 indexed citations

Konstantinopoulos, Panagiotis A., Mingyang Cai, Niya Xiong, et al.. (2024). Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC).. Journal of Clinical Oncology. 42(16_suppl). 5592–5592.

10.

Matoba, Yusuke, Eugene Kim, Amy Bregar, et al.. (2023). Mechanisms of resistance to bispecific T-cell engager therapy for ovarian cancer.. Journal of Clinical Oncology. 41(16_suppl). 5571–5571. 1 indexed citations

11.

Moore, Kathleen N., Vicky Makker, Oladapo Yeku, et al.. (2023). #430 DB-1303, a HER2-targeting ADC, for patients with advanced/metastatic endometrial cancer: preliminary clinical results from an ongoing phase 1/2a trial (NCT05150691). A9–A10. 2 indexed citations

12.

Corcoran, Ryan B., T. Khanh, James M. Cleary, et al.. (2023). 664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors. Annals of Oncology. 34. S467–S467. 1 indexed citations

13.

Starodub, Alexander, S-B. Kim, Diwakar Davar, et al.. (2023). 1034P Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy. Annals of Oncology. 34. S628–S628. 2 indexed citations

14.

Ramos, Azucena, et al.. (2022). Three Cases of Atypical Cutaneous Ovarian Metastases: A Single-Center Case Series. SHILAP Revista de lepidopterología. 1(9).

15.

Yeku, Oladapo, et al.. (2022). 159P COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant epithelial ovarian cancer. Immuno-Oncology Technology. 16. 100271–100271. 1 indexed citations

16.

Yeku, Oladapo, Arielle J. Medford, Andrew Z. Fenves, & Sacha Uljon. (2021). Case 15-2021: A 76-Year-Old Woman with Nausea, Diarrhea, and Acute Kidney Failure. New England Journal of Medicine. 384(20). 1943–1950.

17.

Song, Mei, Oladapo Yeku, Sarwish Rafiq, et al.. (2020). Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nature Communications. 11(1). 6298–6298. 111 indexed citations

18.

Russo, Andrea, et al.. (2020). Effect of Mismatch Repair Status on Outcome of Early Stage Grade 1-2 Endometrial Cancer Treated With Vaginal Brachytherapy. International Journal of Radiation Oncology*Biology*Physics. 108(3). e457–e458. 1 indexed citations

19.

Rafiq, Sarwish, Oladapo Yeku, Terence J. Purdon, et al.. (2018). Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nature Biotechnology. 36(9). 847–856. 628 indexed citations breakdown →

20.

Su, Wenjuan, Oladapo Yeku, O. Srinivas, et al.. (2008). 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a Phospholipase D Pharmacological Inhibitor That Alters Cell Spreading and Inhibits Chemotaxis. Molecular Pharmacology. 75(3). 437–446. 198 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact